Strategic Financial Concepts LLC Invests $1.46 Million in Illumina, Inc. (NASDAQ:ILMN)

Strategic Financial Concepts LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 10,958 shares of the life sciences company’s stock, valued at approximately $1,464,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ILMN. Cetera Investment Advisers boosted its stake in shares of Illumina by 25.8% in the 2nd quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock worth $1,919,000 after buying an additional 3,767 shares during the last quarter. CWM LLC boosted its stake in shares of Illumina by 179.8% in the 3rd quarter. CWM LLC now owns 16,207 shares of the life sciences company’s stock worth $2,114,000 after buying an additional 10,414 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in shares of Illumina by 323.9% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,047 shares of the life sciences company’s stock worth $136,000 after buying an additional 800 shares during the last quarter. Valeo Financial Advisors LLC purchased a new position in Illumina in the third quarter valued at approximately $276,000. Finally, Compagnie Lombard Odier SCmA lifted its stake in Illumina by 2,013.3% in the third quarter. Compagnie Lombard Odier SCmA now owns 1,585 shares of the life sciences company’s stock valued at $207,000 after purchasing an additional 1,510 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 5.5 %

Shares of ILMN stock opened at $104.99 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock has a market capitalization of $16.65 billion, a P/E ratio of -13.67 and a beta of 1.10. The company has a 50 day moving average price of $136.70 and a 200 day moving average price of $135.56. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. Equities research analysts predict that Illumina, Inc. will post 4.42 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Barclays downgraded Illumina from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $130.00 to $100.00 in a research note on Monday. Guggenheim dropped their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday. UBS Group boosted their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Robert W. Baird boosted their target price on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group lowered their target price on shares of Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a report on Friday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Illumina presently has an average rating of “Moderate Buy” and an average price target of $160.15.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.